Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 31/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 31/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/5/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 31/5/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 31/5/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -0.31% | +5.79% | +47.13% | +99.53% | 70.88B | |
| -0.62% | -0.21% | +37.20% | +82.85% | 62.49B | |
| +5.26% | +7.86% | +32.24% | +30.06% | 26.34B | |
| -3.21% | -7.27% | -17.10% | +370.22% | 26.21B | |
| -2.64% | -0.69% | -0.17% | -11.56% | 24.13B | |
| -1.00% | +5.72% | +23.22% | -12.34% | 20.72B | |
| +2.12% | -5.86% | +161.58% | +333.73% | 15.69B | |
| -0.22% | +3.99% | +45.54% | +171.32% | 14.46B | |
| +0.73% | +1.71% | -5.51% | +859.68% | 14.24B | |
| Average | +0.02% | +1.74% | +36.01% | +213.72% | 30.57B | |
| Weighted average by Cap. | -0.18% | +1.49% | +35.10% | +153.18% |
Employees
31
